Macrogenics (MGNX) Operating Income (2012 - 2026)
Macrogenics (MGNX) posted quarterly Operating Income of -$33.4 million for Q1 2026, up 21.55% year-over-year from -$27.5 million in Q1 2025, and down 176.42% quarter-over-quarter from -$12.1 million in Q4 2025.
Macrogenics (MGNX) Operating Income (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Operating Income for 15 consecutive years, with -$33.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income rose 21.55% year-over-year to -$33.4 million; the TTM figure through Mar 2026 stood at -$63.7 million (up 35.99% YoY), while the FY2025 annual figure was -$72.8 million, up 34.13% from the prior year.
- Operating Income eased to -$33.4 million in Q1 2026 per MGNX's latest filing, from -$12.1 million in the prior quarter.
- Across five years, Operating Income topped out at $54.2 million in Q3 2024 and bottomed at -$66.6 million in Q1 2022.
- Historically, Operating Income has averaged -$29.8 million across 5 years, with a median of -$38.4 million in 2023.
- Annual changes were most pronounced in 2023 — Operating Income plunged 511.87% — and 2024, when it soared 252.64%.
- Macrogenics' Operating Income stood at $12.0 million in 2022, then slumped by 511.87% to -$49.4 million in 2023, then slipped by 7.06% to -$52.8 million in 2024, then jumped by 77.11% to -$12.1 million in 2025, then slumped by 176.42% to -$33.4 million in 2026.
- Business Quant data shows MGNX's Operating Income at -$33.4 million in Q1 2026, -$12.1 million in Q4 2025, and $18.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - | -33.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.44 Mn |
| Dec 31, 2025 | -12.10 Mn |
| Sep 30, 2025 | 18.64 Mn |
| Jun 30, 2025 | -36.76 Mn |
| Mar 31, 2025 | -42.62 Mn |
| Dec 31, 2024 | -52.84 Mn |
| Sep 30, 2024 | 54.19 Mn |
| Jun 30, 2024 | -58.18 Mn |
| Mar 31, 2024 | -53.75 Mn |
| Dec 31, 2023 | -49.35 Mn |
| Sep 30, 2023 | -35.50 Mn |
| Jun 30, 2023 | -44.96 Mn |
| Mar 31, 2023 | -38.43 Mn |
| Dec 31, 2022 | 11.98 Mn |
| Sep 30, 2022 | -24.96 Mn |
| Jun 30, 2022 | -41.81 Mn |
| Mar 31, 2022 | -66.64 Mn |
| Dec 31, 2021 | -58.24 Mn |
| Sep 30, 2021 | -52.99 Mn |
| Jun 30, 2021 | -40.28 Mn |